Patients who are treated with prostate cancer drug depot therapy and whose PSA drops to a low level (usually below 0.2ng/ml) can stop the drug under the guidance of their doctor and wait until the PSA rises before adding more drugs, an approach called intermittent endocrine therapy. Generally speaking, as long as the PSA is not too high when prostate cancer is diagnosed, intermittent treatment is recommended, especially for patients whose prostate cancer is in the early to mid-stage but who cannot afford radical surgery for medical reasons. During discontinuation, the anemia, sexual dysfunction, flushing and other side effects caused by lowered androgens will improve, resulting in a better quality of life for the patient, who will then be more willing to follow medical advice; this modality can also delay the time to drug resistance and delay the onset of destructive resistant prostate cancer. ”Can intermittent treatment prolong the life of prostate cancer patients compared to continuous treatment?” — There is really no definitive answer as to which approach prolongs survival longer, but intermittent treatment has a better quality of life and cost of treatment compared to continuous treatment. Intermittent medication, after stopping the medication patients are also checked PSA once in three months, if PSA is found to be elevated in both examinations, it should be closely monitored and changed to once a month, once PSA is found to be more than 2ng/ml in the examination (see “What does elevated PSA mean after endocrine therapy for prostate cancer?”) , it will be necessary to use the medication again.